Inventiva reshuffled its leadership team as it prepares for a Phase III readout for lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH) targeted for 4Q26. The company named a new CFO, chief legal officer, and chief people officer as it adds senior executives to its C-suite. Axel-Sven Malkomes, previously CFO of CureVac, becomes CFO; Susan Coles returns as chief legal officer after previously holding leadership roles at Vivet Therapeutics; and Pamela Herbster is appointed chief people officer following HR and business operations leadership at Sage Therapeutics. The changes come as Inventiva approaches late-stage catalysts, with governance and finance execution often scrutinized ahead of major trial readouts for hepatology programs.